cd86 fc (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
94
Structured Review
R&D Systems
cd86 fc
Cd86 Fc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd86/Recombinant+Human+B7-2%2FCD86+Fc+Chimera+Protein%2C+CF/us12589163-1148-15-16
Average 94 stars, based on 4 article reviews
Cd86 Fc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd86/Recombinant+Human+B7-2%2FCD86+Fc+Chimera+Protein%2C+CF/us12589163-1148-15-16
Average 94 stars, based on 4 article reviews
cd86 fc - by Bioz Stars,
2026-10
94/100 stars
Images
Related Articles
other:Article Title: Amino acid sequences that modulate the interaction between cells of the immune system Article Snippet: Suitable techniques for generating such immunoglobulin sequences will be clear to the skilled person, and for example include the screening techniques reviewed by Hoogenboom, Nature Biotechnology, 23, 9, 1105-1116 (2005) Other techniques for generating immunoglobulins against a specified target include for example the Nanoclone technology (as for example described in the published US patent application 2006-0211088), so-called SLAM technology (as for example described in the European patent application 0 542 810), the use of transgenic mice expressing human immunoglobulins or the well-known hybridoma techniques (see for example Larrick et al, Biotechnology, Vol. Article Title: Polypeptides that modulate the interaction between cells of the immune system Article Snippet: Suitable techniques for generating such immunoglobulin sequences will be clear to the skilled person, and for example include the screening techniques reviewed by Hoogenboom, Nature Biotechnology, 23, 9, 1105-1116 (2005) Other techniques for generating immunoglobulins against a specified target include for example the Nanoclone technology (as for example described in the published US patent application 2006-0211088), so-called SLAM technology (as for example described in the European patent application 0 542 810), the use of transgenic mice expressing human immunoglobulins or the well-known hybridoma techniques (see for example Larrick et al, Biotechnology, Vol. Article Title: Amino acid sequences that modulate the interaction between cells of the immune system Article Snippet: Suitable techniques for generating such immunoglobulin sequences will be clear to the skilled person, and for example include the screening techniques reviewed by Hoogenboom, Nature Biotechnology, 23, 9, 1105-1116 (2005) Other techniques for generating immunoglobulins against a specified target include for example the Nanoclone technology (as for example described in the published US patent application 2006-0211088), so-called SLAM technology (as for example described in the European patent application 0 542 810), the use of transgenic mice expressing human immunoglobulins or the well-known hybridoma techniques (see for example Larrick et al, Biotechnology, Vol. Recombinant:Article Title: Amino acid sequences that modulate the interaction between cells of the immune system Article Snippet: A fusion protein consisting of the extracellular part of human CD86 and human Fc gamma 1 was obtained from R&D Systems as a recombinant protein produced in NS0 cells (Cat #140-B2). .. A fusion protein consisting of the extracellular part of Article Title: Co-expression plasmid Article Snippet: .. As samples, a mixture of 1 nM anti-hCTLA-4scFv01-FLAG obtained by FLAG-tag purification from co-expression strain PC4 and human CD80 (Recombinant Human B7-1/CD80 Fc Chimera, R&D Systems, hereinafter referred to as hCD80) different in concentration (30 nM, 20 nM, 10 nM, 5 nM, 3 nM and 0 nM); and a mixture of 1 nM anti-hCTLA-4 scFv01-FLAG and Article Title: Amino acid sequences that modulate the interaction between cells of the immune system Article Snippet: A fusion protein consisting of the extracellular part of human CD86 and human Fc gamma 1 was obtained from R&D Systems as a recombinant protein produced in NS0 cells (Cat #140-B2). .. A fusion protein consisting of the extracellular part of Produced:Article Title: Amino acid sequences that modulate the interaction between cells of the immune system Article Snippet: A fusion protein consisting of the extracellular part of human CD86 and human Fc gamma 1 was obtained from R&D Systems as a recombinant protein produced in NS0 cells (Cat #140-B2). .. A fusion protein consisting of the extracellular part of Article Title: Amino acid sequences that modulate the interaction between cells of the immune system Article Snippet: A fusion protein consisting of the extracellular part of human CD86 and human Fc gamma 1 was obtained from R&D Systems as a recombinant protein produced in NS0 cells (Cat #140-B2). .. A fusion protein consisting of the extracellular part of FLAG-tag:Article Title: Co-expression plasmid Article Snippet: .. As samples, a mixture of 1 nM anti-hCTLA-4scFv01-FLAG obtained by FLAG-tag purification from co-expression strain PC4 and human CD80 (Recombinant Human B7-1/CD80 Fc Chimera, R&D Systems, hereinafter referred to as hCD80) different in concentration (30 nM, 20 nM, 10 nM, 5 nM, 3 nM and 0 nM); and a mixture of 1 nM anti-hCTLA-4 scFv01-FLAG and Purification:Article Title: Co-expression plasmid Article Snippet: .. As samples, a mixture of 1 nM anti-hCTLA-4scFv01-FLAG obtained by FLAG-tag purification from co-expression strain PC4 and human CD80 (Recombinant Human B7-1/CD80 Fc Chimera, R&D Systems, hereinafter referred to as hCD80) different in concentration (30 nM, 20 nM, 10 nM, 5 nM, 3 nM and 0 nM); and a mixture of 1 nM anti-hCTLA-4 scFv01-FLAG and Concentration Assay:Article Title: Co-expression plasmid Article Snippet: .. As samples, a mixture of 1 nM anti-hCTLA-4scFv01-FLAG obtained by FLAG-tag purification from co-expression strain PC4 and human CD80 (Recombinant Human B7-1/CD80 Fc Chimera, R&D Systems, hereinafter referred to as hCD80) different in concentration (30 nM, 20 nM, 10 nM, 5 nM, 3 nM and 0 nM); and a mixture of 1 nM anti-hCTLA-4 scFv01-FLAG and |